Cipla Points To Large GLP-1 India Opportunity Amid Speculation On Lilly Deal
Executive vice chair Samina Hamied moves to non-exec role
Cipla refers to the transformational potential of GLP-1s in India, a market with 100m-plus diabetics and rising obesity, amid plans for oral semaglutide and speculation on partnering possibilities. A recalibration in the firm’s specialty products thrust is also seen.
